In 2024, ADA guidelines were updated to represent weight management as a primary goal of treatment along with glycemic management in people with T2D and overweight or obesity
That is a major red flag for counterfeit or unapproved products
Collectively, these findings show that tirzepatide produces weight loss at levels comparable to or greater than existing therapies, even in populations without T2D
[2] Other GLP-1 receptor agonists may be considered, though they share similar mechanisms and potential side effects: Injectable GLP-1 agonists such as dulaglutide (Trulicity), liraglutide (Victoza), or exenatide (Byetta) may be better tolerated by some patients, as they bypass the upper gastrointestinal tract
Toddlers go through various stages of sleep, including non-REM and REM sleep
Oncogene 18 (44), 60136020